Junshi Joins China mRNA Mania Through Immorna JV
Latest Partner For In-Demand Venture
Executive Summary
After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.
You may also be interested in...
Asia Deal Watch: GC Pharma Looks To Build On Enzyme Replacement Therapy Success
South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder and with Mirum for maralixibat. Plus deals involving Takeda/PeptiDream, Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.
Selling More For Less In China Pays Off For AstraZeneca
Volume gains from the entry into China’s national reimbursement program offset deep price cut for AstraZeneca’s major selling Tagrisso in the second quarter of 2021.
Novartis China Drive Paying Off, Sales Soar On Reimbursement Inclusion
Sales of the Swiss drug maker's major plaque psoriasis treatment Cosentyx in China quadrupled in the second quarter, despite its price being slashed by more than 60%.